Robert Jotte, MD, PhD, discusses findings from the phase 3 KRYSTAL-12 study evaluating adagrasib in KRAS G12C-mutated NSCLC.
Robert Jotte, MD, PhD
Robert Jotte, MD, PhD, is a medical oncologist/hematologist at Rocky Mountain Cancer Centers.
Articles by Robert Jotte, MD, PhD